Grifols in talks with several funds to carry out EUR 2bn capital increase
Grifols negociaría con varios fondos una ampliación de capital de hasta EUR 2.000m
Intel ID : 347117
|
||||
| Intel ID | 347117 | |
| Value | EUR 2.000,00m | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Grifols
(31 Dec 2023) |
Revenue: EUR 7.077,97m EBITDA: EUR 1.247,56m Net Debt: EUR 10.541,45m |
|
| Date |
 |
|
| Country | |
|
| Geography |  |
|
| Subsector (Old TTR Sectors) |
|
|
| Primary Subsector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Financial Advisory
| Parties | Advisor | Notes from Advisors | |||||
|---|---|---|---|---|---|---|---|
|
|
- |
Radar
| Date | Title | Type | Intel Grade | Country | Subsector | ||
|
|
|
|
|
|
|
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.